259 related articles for article (PubMed ID: 2871585)
1. The effect of antirheumatic drugs on circulating immune complexes in rheumatoid arthritis.
Forster PJ; McConkey B
Q J Med; 1986 Jan; 58(225):29-42. PubMed ID: 2871585
[TBL] [Abstract][Full Text] [Related]
2. Circulating microparticles remain associated with complement activation despite intensive anti-inflammatory therapy in early rheumatoid arthritis.
van Eijk IC; Tushuizen ME; Sturk A; Dijkmans BA; Boers M; Voskuyl AE; Diamant M; Wolbink GJ; Nieuwland R; Nurmohamed MT
Ann Rheum Dis; 2010 Jul; 69(7):1378-82. PubMed ID: 19919943
[TBL] [Abstract][Full Text] [Related]
3. Clinical and laboratory effects of prolonged therapy with sulfasalazine, gold or penicillamine: the effects of disease duration on treatment response.
Situnayake RD; McConkey B
J Rheumatol; 1990 Oct; 17(10):1268-73. PubMed ID: 1979349
[TBL] [Abstract][Full Text] [Related]
4. Effect of antimalarial treatment on circulating immune complexes in rheumatoid arthritis.
Segal-Eiras A; Segura GM; Babini JC; Arturi AS; Fraguela JM; Marcos JC
J Rheumatol; 1985 Feb; 12(1):87-9. PubMed ID: 3981522
[TBL] [Abstract][Full Text] [Related]
5. Circulating immune complexes in rheumatoid arthritis. Selective removal by cryogelation with membrane filtration.
Krakauer RS; Asanuma Y; Zawicki I; Calabrese L; Malchesky P; Nose Y
Arch Intern Med; 1982 Feb; 142(2):395-7. PubMed ID: 6977346
[TBL] [Abstract][Full Text] [Related]
6. Immune complexes in early arthritis. L Detection of immune complexes before rheumatoid arthritis is definite.
Jones VE; Jacoby RK; Wallington T; Holt P
Clin Exp Immunol; 1981 Jun; 44(3):512-21. PubMed ID: 6976861
[TBL] [Abstract][Full Text] [Related]
7. [The effect of treatment on circulating immune complexes in rheumatoid arthritis (author's transl)].
Rosenthal M; Graf U; Müller W
Dtsch Med Wochenschr; 1977 Mar; 102(12):415-8. PubMed ID: 844411
[TBL] [Abstract][Full Text] [Related]
8. Relationship between the articular manifestations of rheumatoid arthritis and circulating immune complexes detected by three methods and specific classes of rheumatoid factors.
Lessard J; Nunnery E; Cecere F; McDuffy S; Pope RM
J Rheumatol; 1983 Jun; 10(3):411-7. PubMed ID: 6604160
[TBL] [Abstract][Full Text] [Related]
9. [Is the demonstration of immune complex useful in the activity assessment of chronic polyarthritis?].
Schlumpf U; Ernst R; Christen P; von Felten A; Böni A
Schweiz Med Wochenschr; 1984 Jan; 114(4):118-30. PubMed ID: 6367028
[TBL] [Abstract][Full Text] [Related]
10. Serum matrix metalloproteinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with early rheumatoid arthritis.
Posthumus MD; Limburg PC; Westra J; van Leeuwen MA; van Rijswijk MH
J Rheumatol; 2002 May; 29(5):883-9. PubMed ID: 12022344
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-6, soluble interleukin-2-receptor and soluble interleukin-6-receptor in sera of patients with rheumatoid arthritis: influences of disease activity and drug therapy.
Franke S; Herrmann D; Hein G; Müller A; Stein G
Eur J Med Res; 1997 Sep; 2(9):401-6. PubMed ID: 9300938
[TBL] [Abstract][Full Text] [Related]
12. Correlation in rheumatoid arthritis of concentrations of plasma C3d, serum rheumatoid factor, immune complexes and C-reactive protein with each other and with clinical features of disease activity.
Mallya RK; Vergani D; Tee DE; Bevis L; de Beer FC; Berry H; Hamilton ED; Mace BE; Pepys MB
Clin Exp Immunol; 1982 Jun; 48(3):747-53. PubMed ID: 6981476
[TBL] [Abstract][Full Text] [Related]
13. Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.
Rau R; Schleusser B; Herborn G; Karger T
J Rheumatol; 1998 Aug; 25(8):1485-92. PubMed ID: 9712088
[TBL] [Abstract][Full Text] [Related]
14. [Circulating immune complexes in a population of subjects seropositive for rheumatoid factor].
Aureli G; Battista V; Bianchi L; Bolzonetti A; Cipriani A; Carnevali GF; Caschera F; Caputo B; Danieli G; Corvetta A
Boll Ist Sieroter Milan; 1982; 61(5):367-74. PubMed ID: 6985415
[TBL] [Abstract][Full Text] [Related]
15. Circulating immune complexes in patients with rheumatoid arthritis: correlation with disease activity.
Levo Y; Fischel R; Ehrenfeld M
J Rheumatol; 1981; 8(5):851-5. PubMed ID: 7310781
[TBL] [Abstract][Full Text] [Related]
16. Effect of spironolactone on endothelial dysfunction in rheumatoid arthritis.
Syngle A; Vohra K; Kaur L; Sharma S
Scand J Rheumatol; 2009; 38(1):15-22. PubMed ID: 18766955
[TBL] [Abstract][Full Text] [Related]
17. Decline of circulating immune complexes in rheumatoid arthritis: patients treated with tiopronine.
Bendaoud B; Delecoeuillerie G; Katsikis P; Le Goff P; Youinou P
Riv Eur Sci Med Farmacol; 1989 Aug; 11(4):291-5. PubMed ID: 2640050
[TBL] [Abstract][Full Text] [Related]
18. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
Bendtzen K; Geborek P; Svenson M; Larsson L; Kapetanovic MC; Saxne T
Arthritis Rheum; 2006 Dec; 54(12):3782-9. PubMed ID: 17133559
[TBL] [Abstract][Full Text] [Related]
19. [Current status of drug therapy in chronic polyarthritis].
Seitz M
Ther Umsch; 1991 Sep; 48(9):613-23. PubMed ID: 1683020
[TBL] [Abstract][Full Text] [Related]
20. Eosinophil involvement in rheumatoid arthritis as reflected by elevated serum levels of eosinophil cationic protein.
Hällgren R; Feltelius N; Svenson K; Venge P
Clin Exp Immunol; 1985 Mar; 59(3):539-46. PubMed ID: 3987090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
